Shionogi B.V.

Founder Saburo Shiono, established the pharmaceutical wholesaler Shiono Saburo Store in Dojima-cho, Osaka, selling traditional Chinese and Japanese medicines.

Saburo Shionogi founded the drug wholesaler "Shiono Saburo Store" at 3-12 Doshomachi, Osaka, on March 17, 1878.

Shifted handling to Western medicines.

In 1886, with the spread of Western medicine, began importing and selling Western medicines.

Started direct dealings with Western trading companies.

Manufacture and sale of the first self-developed drug, Antachin, an antacid: trademark registration for the weight scale mark.

In 1909, Jiro Chōjiro began trial manufacturing of antacid and produced the product "Antadizen".

In 1909, registered the trademark of the weighing scale mark, a symbol of trust and credibility.

Constructed Shiono Pharmaceutical Plant in Fukushima-ku, Osaka.

In 1910, built the "Shiono Pharmaceutical Plant" and started full-scale production of new drugs.

In 1912, introduced the new heart medicine "Digamin" through the introduction by Heizo Kondo.

Merged Shiono Saburo Store and Shiono Pharmaceutical Plant, reorganized into Shiono Pharmaceutical Co., Ltd.

In 1919, merged the drug wholesaler managed by Saburo Giso and the pharmaceutical business led by his younger brother Chōjirō, establishing "Shiono Gijutsu Co., Ltd.".

Established Kakezu Factory in Amagasaki City, Hyogo Prefecture (now Kakezu Business Office), with a research laboratory inside the factory.

Constructed a new headquarters building in Dojima-cho, Osaka.

Changed the company name to Shiono Gishi Pharmaceutical Co., Ltd.

In 1943, changed the company name to Shiono Gijutsu Pharmaceutical Co., Ltd.

In 1945, due to post-war inflation and economic turmoil, management deteriorated; Giso promoted technology withdrawal and cost reduction to improve management.

Established Aburahi Farm in Shiga Prefecture (now Aburahi Business Office).

株式上場（東京、大阪両証券取引所）

Launched painkiller Cedes.

In 1950, launched the painkiller "Sedes".

Launched comprehensive vitamin Popon S.

Since 1953, various business developments and management policy changes occurred.

Formulated basic policy.

In 1957, inherited a corporate culture emphasizing better product manufacturing, accurate sales, and technological development.

Discovered Shinomin: established the Ditealman system.

Launched sulfa drug Shinomin.

Constructed the Central Research Institute in Fukushima-ku, Osaka (now consolidated into the Pharmaceutical Research Center).

Established Animal Pharmaceuticals Department (transferred in 2002), Plant Pharmaceuticals Department (transferred in 2001), and started operations of the Clinical Testing Laboratory (transferred in 2002): established Taiwan Shiono Gishi Pharmaceutical Co., Ltd.

Started broadcasting the one-company sponsored program 'Shiono Gigi Music Fair'.

Built Setsu Factory in Settsu City, Osaka Prefecture.

Established Nia Pharmaceuticals Co., Ltd. (now Shiono Gishi Pharma Co., Ltd.).

Construction of Shionogi Shibuya Building (Tokyo, Shibuya Ward): Construction of New Drug Research Institute (Osaka, Toyonaka City) (Current: Pharmaceutical Research Center)

Launch of oxacefem antibiotic "Shiomarin"

Since 1982, reorganization and overseas expansion progressed, including transfer of plant medicines and animal medicines, establishment of U.S. subsidiaries, and partnership with GlaxoSmithKline in the UK.

Construction of Kanegasaki Factory (Iwate Prefecture)

Construction of Medical Science Research Institute (within Settsu Factory site) (Current: Consolidated into Pharmaceutical Research Center): Launch of oxacefem antibiotic "Furmarin"

Establishment of Shionogi General Service Inc. (Current: Shionogi Business Partner Inc.): Acquisition of capsule business from Eli Lilly & Co. (sold in 2005)

Construction of new headquarters building (Osaka, Doshomachi)

Launch of cephamycin antibiotic "Flomox"

Formulation of Shionogi Code of Conduct (revised in 2012): Establishment of Omori Pharmaceutical Co., Ltd. (sold in 2002): Establishment of Bushu Pharmaceutical Co., Ltd. (sold in 2010)

Start of the 1st Mid-term Management Plan

Establishment of Shionogi USA, Inc. (now Shionogi Inc.): Establishment of overseas JV: Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC) and start of joint research and development of HIV infection drugs

Launch of cancer pain treatment drug "OxyContin"

Start of the 2nd Mid-term Management Plan: Launch of high cholesterol treatment drug "Crestor": Launch of carbapenem antibiotic "FiniBax"

Since 2005, we have advanced acquisitions of overseas companies, establishment of subsidiaries, and joint development, building a global research and development system.

Establishment of Shionogi Analysis Center Inc.: Launch of cancer pain treatment powder "Okinom"

Acquisition of US Sciele Pharma, Inc. (now Shionogi Inc.): Opening of joint research facility with Hokkaido University, Shionogi Drug Discovery Innovation Center: Launch of antihypertensive drug "Irbetan": Launch of acne treatment drug "Diflin": Launch of idiopathic pulmonary fibrosis drug "Pirespa"

Start of the 3rd Mid-term Management Plan: Establishment of Shionogi Techno Advance Research Inc.: Opening of PET molecular imaging center at Osaka University Graduate School of Medicine: Launch of anti-influenza drug "Rapiacta": Launch of antidepressant "Simbalta"

Acquisition of Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited: Construction of new research building SPRC4 within Pharmaceutical Research Center (SPRC) to consolidate drug discovery research functions

Establishment of European subsidiary Shionogi Limited (UK): Signing of new framework agreement with VeeHealthCare for HIV infection treatment drugs: Launch of cancer pain treatment injection "OkiFast": Launch of antihypertensive drug "Aimix"

Establishment of Beijing Shionogi Pharmaceutical Technology Co., Ltd. (China): Establishment of Shionogi Singapore Pte. Ltd.: Modification of royalty agreement with AstraZeneca for Crestor: Launch of postmenopausal vaginal atrophy treatment "Osphena" in the US: Launch of antihypertensive drug "Ilutra"

Start of mid-term management plan "Shionogi Growth Strategy 2020 (SGS2020)": Launch of HIV infection treatment drug "Tebikei"

In 2014, we formulated a mid-term management plan aiming for growth as a drug discovery pharmaceutical company, and promoted improvement of ROE and focus on drug discovery.

Launch of HIV infection treatment drug "Trimek": Launch of allergen immunotherapy drug "Asitea": Launch of thrombocytopenia treatment drug "Mulpreta"

Update of the medium-term management plan "SGS2020": Establishment of Shionogi Healthcare Co., Ltd.: Launch of cholesterol-lowering drug "Crestor OD Tablets"

Establishment of domestic group companies: Shionogi Carrier Development Center Inc., Shionogi Digital Science Inc., Shionogi Business Partners Inc., Shionogi Pharmacovigilance Center Inc., Shionogi Marketing Solutions Inc.: Launch of cancer pain treatment drug "Mesapain": Launch of attention deficit/hyperactivity disorder treatment drug "Inchunib": Launch of opioid-induced constipation treatment drug "Symproic" in the U.S.: Launch of opioid-induced constipation treatment drug "Swinproic": Launch of sustained cancer pain treatment "OxyContin TR Tablets"

Establishment of Shionogi Pharma Inc.: Establishment of European subsidiary Shionogi B.V.: Launch of anti-influenza virus drug "Zofluza": Launch of thrombocytopenia treatment drug "Mulpleta" in the U.S.: Launch of anti-HIV drug "Jalka"

Establishment of joint venture with M3 Inc., "Stream Eye Co., Ltd.": Acquisition of a consolidated subsidiary of UMN Pharma Inc.: Opening of Shionogi Education and Training Center in Amagasaki City: Launch of opioid-induced constipation treatment drug "Rizmoic" in Europe: Launch of influenza virus drug "Shufuxiao" in Taiwan: Launch of attention deficit/hyperactivity disorder treatment drug "Vibance"

Start of the mid-term management plan "Shionogi Transformation Strategy 2030 (STS2030)": Establishment of joint venture with Ping An Insurance in China, "Ping An Shionogi Co., Ltd.": Full acquisition of U.S. Tetra Inc.: Acquisition of Nagase Pharmaceuticals by Shionogi Pharma: Launch of gram-negative bacterial infection treatment drug "Fetroja" in the U.S.: Launch of gram-negative bacterial infection treatment drug "Fetcroja" in Europe

Start of sewage epidemiology survey service for COVID-19: Launch of opioid-induced constipation treatment drug "Swinproic" in Taiwan

Establishment of joint venture with Shimadzu Corporation, "AdvanSentinel Inc.": Establishment of general incorporated foundation "Shionogi Infectious Disease Research Promotion Foundation": Building of SHIONOGI group brand and establishment of group brand mark: Establishment of Yui Connection Inc.: Launch of COVID-19 treatment drug "Zocova"